Q2 2021 Results - Reimagining Medicine

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations ECF843-rh-Lubricin Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04391894 (CECF843A2201) Dry eye Phase 2 680 Change from baseline in symptom assessment in Dry Eye (SANDE) score Change from baseline in composite corneal fluorescein staining score A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects with dry eye disease ECF843 0.15 or 0.45 mg/mL BID/TID/vehicle Patients with moderate to severe dry eye disease (DED) Target Patients Read-out Milesstone(s) Publication TBD H2-2021 (actual) 123 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation